Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Dare Bioscience (DARE) over the last 8 years, with Q3 2025 value amounting to $181041.0.

  • Dare Bioscience's Change in Receivables rose 15095.31% to $181041.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$149729.0, marking a year-over-year increase of 7548.93%. This contributed to the annual value of -$719229.0 for FY2024, which is 460.5% up from last year.
  • Per Dare Bioscience's latest filing, its Change in Receivables stood at $181041.0 for Q3 2025, which was up 15095.31% from $82882.0 recorded in Q2 2025.
  • Over the past 5 years, Dare Bioscience's Change in Receivables peaked at $9.4 million during Q2 2022, and registered a low of -$8.9 million during Q3 2022.
  • In the last 5 years, Dare Bioscience's Change in Receivables had a median value of -$124748.0 in 2025 and averaged -$4790.1.
  • Within the past 5 years, the most significant YoY rise in Dare Bioscience's Change in Receivables was 115055.6% (2021), while the steepest drop was 778434.68% (2021).
  • Over the past 5 years, Dare Bioscience's Change in Receivables (Quarter) stood at $989070.0 in 2021, then tumbled by 159.54% to -$588882.0 in 2022, then surged by 69.34% to -$180547.0 in 2023, then tumbled by 60.02% to -$288904.0 in 2024, then skyrocketed by 162.66% to $181041.0 in 2025.
  • Its Change in Receivables was $181041.0 in Q3 2025, compared to $82882.0 in Q2 2025 and -$124748.0 in Q1 2025.